Clinical Trial Search

Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) — 1.2 mg/kg

Primary: Overall Survival — 0; 0 Proportion of participants

Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion

Primary: Median Progression Free Survival (PFS) — 13.8 years

Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…

Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr

Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months

Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911

Primary: Complete Response Rate — 34 Participants

Primary: Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II) — 67.5; 76.2 percentage of participants

Primary: ORR Assess by IRC — 76.0 percentage

Primary: Failure-free Survival at 5 Years — 0.74; 0.71 Proportion of patients — p=0.32

Primary: Progression-free Survival (PFS) — 18 participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…

Primary: Progression-free Survival (PFS) — 89.7; 50 percentage of participants

Primary: Complete Remission — 10 participants

Primary: Objective Response — 3; 6; 3; 2 participants

Primary: Transplant Related Mortality Rate — 1; 6 Participants

Primary: Overall Response Rate — 20.0 percentage of participants

Primary: Progression-free Survival — 18 participants

Primary: Effect of Rituximab on EBV(+) Tumors — 0 relapses

Primary: Overall Response — 3 participants

Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival

Primary: Event-free Survival (EFS) Rate — 17; 20 Participants

Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants

Primary: Overall Response Rate (ORR) — 82 Participants

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…